OncoMatch/Clinical Trials/NCT06232044
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Is NCT06232044 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Belantamab Mafodotin and Iberdomide for recurrent multiple myeloma.
Treatment: Iberdomide · Belantamab Mafodotin · Dexamethasone — This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Multiple myeloma is a cancer that affects white blood cells called plasma cells, which are made in the bone marrow and are part of the immune system. Multiple myeloma cells have a protein on their surface called B-cell maturation antigen (BCMA) that allows the cancer cells to survive and grow. Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Belantamab mafodotin has been designed to attach to the BCMA protein, which may cause the myeloma cell to become damaged and die. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Iberdomide plus belantamab mafodotin may help slow or stop the growth of cancer in patients with multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulatory derivative — exposed/refractory
triple-class exposed (exposed /refractory to an immunodulatory derivative (IMiD) and/or proteasome inhibitors (PI) and/or to daratumumab or other anti-CD38 monoclonal antibody)
Must have received: proteasome inhibitor — exposed/refractory
triple-class exposed (exposed /refractory to an immunodulatory derivative (IMiD) and/or proteasome inhibitors (PI) and/or to daratumumab or other anti-CD38 monoclonal antibody)
Must have received: anti-CD38 monoclonal antibody (daratumumab) — exposed/refractory
triple-class exposed (exposed /refractory to an immunodulatory derivative (IMiD) and/or proteasome inhibitors (PI) and/or to daratumumab or other anti-CD38 monoclonal antibody)
Cannot have received: (iberdomide, belamaf)
No prior exposure to iberdomide or belamaf.
Cannot have received: BCMA-directed therapy
No prior BCMA-directed therapy.
Cannot have received: monoclonal antibody
Exception: within 2 weeks of registration
No prior treatment with a monoclonal antibody within 2 weeks of registration.
Cannot have received: allogeneic stem cell transplant
Exception: syngeneic transplant allowed if no history of or no currently active GvHD
No prior allogeneic stem cell transplant. NOTE: Participants who have undergone syngeneic transplant will be allowed only if no history of or no currently active GvHD.
Cannot have received: plasmapheresis
Exception: within 7 days prior to registration
No plasmapheresis within 7 days prior to registration.
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1,000/mm^3. Platelet count ≥ 75,000/mm^3 (or ≥ 50,000/mm^3 in Phase II if BM plasma cells > 50%).
Kidney function
Calculated creatinine clearance ≥ 30 mL/min using Cockcroft-Gault equation. Spot urine (albumin/creatinine ratios) < 500 mg/g (56 mg/mmol) OR urine dipstick ≥ 1+ if confirmed.
Liver function
Total bilirubin ≤ 2 mg/dL. AST/ALT ≤ 2.5 x ULN. Alkaline phosphatase ≤ 3 x ULN.
Cardiac function
No evidence of current clinically significant uncontrolled arrhythmias, including clinically significant ECG abnormalities such as 2nd degree (Mobitz Type II) or 3rd degree AV block. No history of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within three (3) months of Screening. No Class III or IV heart failure as defined by the New York Heart Association functional classification system. No uncontrolled hypertension. No congenital long QT syndrome, QTcF interval > 480 msec. No history of ventricular fibrillation or torsade de pointes. No symptomatic bradycardia defined as HR < 50 bpm with associated dizziness/syncope. Left ventricular ejection fraction < 30%.
Absolute neutrophil count (ANC) ≥ 1,000/mm^3. Platelet count ≥ 75,000/mm^3 (or ≥ 50,000/mm^3 in Phase II if BM plasma cells > 50%). Calculated (Calc.) creatinine clearance ≥ 30 mL/min using Cockcroft-Gault equation. Spot urine (albumin/creatinine ratios) < 500 mg/g (56 mg/mmol) OR urine dipstick ≥ 1+ if confirmed. Total bilirubin ≤ 2 mg/dL. Aspartate aminotransferase (AST)/alanine transaminase (ALT) ≤ 2.5 x upper limit of normal (ULN).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mary Greeley Medical Center · Ames, Iowa
- McFarland Clinic - Ames · Ames, Iowa
- McFarland Clinic - Boone · Boone, Iowa
- McFarland Clinic - Trinity Cancer Center · Fort Dodge, Iowa
- McFarland Clinic - Jefferson · Jefferson, Iowa
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify